The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The authorization of bortezomib will enhance the company’s ability to deliver advanced cancer solutions in Southeast Asia
The Central government’s decision to exempt three more cancer medicines from customs duty is a commendable step towards making cancer drugs more affordable
The company has been entrusted with the responsibility of supplying a wide range of essential oncology drugs
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Subscribe To Our Newsletter & Stay Updated
